Literature DB >> 2810441

Massive insulin overdose: detailed studies of free insulin levels and glucose requirements.

M H Samuels1, R H Eckel.   

Abstract

The course of a diabetic patient who self-administered 2500 U of NPH insulin subcutaneously was examined in detail. Despite resumption of oral intake on day 3, she required iv glucose for 6 days, during which time serum free insulin levels remained elevated. Glucose requirements closely matched those calculated from published euglycemic clamp data on maximal glucose disposal rates during insulin infusion. We postulate that her prolonged course was due to delayed absorption of the subcutaneous insulin. This is the first case of massive insulin overdose studied in such detail, and the results may facilitate management of future cases.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2810441     DOI: 10.3109/15563658909038579

Source DB:  PubMed          Journal:  J Toxicol Clin Toxicol        ISSN: 0731-3810


  5 in total

1.  Characteristics of fatal insulin overdoses.

Authors:  Lilli Stephenson; Corinna van den Heuvel; Melissa Humphries; Roger W Byard
Journal:  Forensic Sci Med Pathol       Date:  2022-08-09       Impact factor: 2.456

Review 2.  Treatment of sulfonylurea and insulin overdose.

Authors:  Wendy Klein-Schwartz; Gina L Stassinos; Geoffrey K Isbister
Journal:  Br J Clin Pharmacol       Date:  2016-01-06       Impact factor: 4.335

3.  Inadvertent iatrogenic insulin detemir 1000 units overdose in a hospitalised patient.

Authors:  Sudan Thapa; Germin Fahim; Sudha Ganne
Journal:  BMJ Case Rep       Date:  2019-12-29

4.  Massive levemir (long-acting) insulin overdose: case report.

Authors:  Mamatha Oduru; Mahmood Ahmad
Journal:  Case Rep Med       Date:  2012-08-09

5.  Intentional overdose with insulin: prognostic factors and toxicokinetic/toxicodynamic profiles.

Authors:  Bruno Mégarbane; Nicolas Deye; Vanessa Bloch; Romain Sonneville; Corinne Collet; Jean-Marie Launay; Frédéric J Baud
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.